发明公开
- 专利标题: SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS
- 专利标题(中): 取代的桥接尿素物作为SIRTUINMODULATOREN
-
申请号: EP14798509.7申请日: 2014-05-13
-
公开(公告)号: EP2997029A1公开(公告)日: 2016-03-23
- 发明人: BLUM, Charles, A. , OALMANN, Christopher , SZCZEPANKIEWICZ, Bruce, G. , CALDWELL, Richard, Dana , CASAUBON, Rebecca , WHITE, Brian, H. , PERNI, Robert, B. , KOPPETSCH, Karsten , DISCH, Jeremy, S. , NG, Pui, Yee , FOX, Ryan, Michael
- 申请人: Glaxosmithkline LLC
- 申请人地址: 2711 Centerville Road Suite 400 Wilmington New Castle, DE 19808 US
- 专利权人: Glaxosmithkline LLC
- 当前专利权人: Glaxosmithkline LLC
- 当前专利权人地址: 2711 Centerville Road Suite 400 Wilmington New Castle, DE 19808 US
- 代理机构: Valentine, Jill Barbara
- 优先权: US201361822758P 20130513
- 国际公布: WO2014186313 20141120
- 主分类号: C07D471/04
- IPC分类号: C07D471/04
摘要:
The present invention relates to novel substituted bridged urea compounds, corresponding related analogs, pharmaceutical compositions and methods of use thereof. Sirtuin-modulating compounds of the present invention may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders, which include, but are not limited to, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity. The present invention also related to compositions comprising a sirtuin-modulating compound in combination with another therapeutic agent.
公开/授权文献
- EP2997029B1 SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS 公开/授权日:2019-01-09
信息查询